Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?

References

• Adams CP, Brantner VV. (2006). Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood ) 25:420–8.
   PubMed Web of Science ®Google Scholar
• Ali AA, Weinstein RS, Stewart SA et al. (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226–35.
   PubMed Web of Science ®Google Scholar
• Arnaud CH. (2006). Systems Biology’s Clinical Future. Chem Eng News 84:17–26.
   Web of Science ®Google Scholar
• Bauer DC, Hunter DJ, Abramson SB et al. (2006). Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14:723–7.
   PubMed Web of Science ®Google Scholar
• Berberoglu Z, Gursoy A, Bayraktar N et al. (2007). Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92:3523–30.
   PubMed Web of Science ®Google Scholar
• Bergmann P, Body JJ, Boonen S et al. (2009). Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 63:19–26.
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Pohl C, Woodworth TG et al. (2009). Developing a standardized definition for disease ‘flare’ in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 36:2335–41.
   PubMed Web of Science ®Google Scholar
• Binkley N, Krueger D, Gemar D et al. (2008). Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93:1804–8.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. (2008). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95.
   Google Scholar
• Black DM, Delmas PD, Eastell R et al. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–22.
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE et al. (2006). Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–38.
   PubMed Web of Science ®Google Scholar
• Bonde M, Qvist P, Fledelius C et al. (1995). Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 80:864–8.
   PubMed Web of Science ®Google Scholar
• Brasso K, Christensen IJ, Johansen JS et al. (2006). Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66:503–13.
   PubMed Web of Science ®Google Scholar
• Broyles DL, Nielsen RG, Bussett EM et al. (1998). Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem 44:2139–47.
   PubMed Web of Science ®Google Scholar
• Caplan L, Saag KG. (2009). Glucocorticoids and the risk of osteoporosis. Expert Opin Drug Saf 8:33–47.
   PubMed Web of Science ®Google Scholar
• Carter GD, Carter CR, Gunter E et al. (2004a). Measurement of vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol 89-90:467–71.
   Web of Science ®Google Scholar
• Carter GD, Carter CR, Jones J et al. (2004b). How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 50:2195–7.
   PubMed Web of Science ®Google Scholar
• Chesnut CH III, Silverman S, Andriano K et al. (2000). A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267–76.
   PubMed Web of Science ®Google Scholar
• Christgau S, Bitsch-Jensen O, Hanover BN et al. (2000). Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505–11.
   PubMed Web of Science ®Google Scholar
• Christgau S, Rosenquist C, Alexandersen P et al. (1998). Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:2290–300.
   PubMed Web of Science ®Google Scholar
• Christgau S, Tanko LB, Cloos PA et al. (2004). Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 11:508–18.
   PubMed Web of Science ®Google Scholar
• Coleman R, Brown J, Terpos E et al. (2008). Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34:629–39.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Bird P, McQueen F et al. (2009). The OMERACT MRI inflammatory arthritis group: advances and future research priorities. J Rheumatol 36:1803–5.
   PubMed Web of Science ®Google Scholar
• Cornish J, Callon KE, Bava U et al. (2002). Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175:405–15.
   PubMed Web of Science ®Google Scholar
• Covey SD, Wideman RD, McDonald C et al. (2006). The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab 4:291–302.
   PubMed Web of Science ®Google Scholar
• Cremers S, Garnero P. (2006). Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 66:2031–58.
   PubMed Web of Science ®Google Scholar
• Delmas PD, Eastell R, Garnero P et al. (2000). The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11 (Suppl. 6):S2–17.
   Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. (2003). The price of innovation: new estimates of drug development costs. J Health Econ 22:151–85.
   PubMed Web of Science ®Google Scholar
• Ducy P, Amling M, Takeda S et al. (2000). Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207.
   PubMed Web of Science ®Google Scholar
• Engvall IL, Svensson B, Tengstrand B et al. (2008). Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther 10:R128.
   PubMed Web of Science ®Google Scholar
• Finley Austin MJ, Babiss L. (2006). Commentary: where and how could biomarkers be used in 2016? AAPS J 8:E185–9.
   PubMed Web of Science ®Google Scholar
• Gale EA. (2001). Lessons from the glitazones: a story of drug development. Lancet 357:1870–5.
   PubMed Web of Science ®Google Scholar
• Gale EA. (2006). Troglitazone: the lesson that nobody learned? Diabetologia 49:1–6.
   PubMed Web of Science ®Google Scholar
• Garnero P, Bianchi F, Carlier MC et al. (2000a). [Biochemical markers of bone remodeling: pre-analytical variations and guidelines for their use. SFBC (Societe Francaise de Biologie Clinique) Work Group. Biochemical markers of bone remodeling]. Ann Biol Clin (Paris) 58:683–704.
   PubMed Web of Science ®Google Scholar
• Garnero P, Ferreras M, Karsdal MA et al. (2003). The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859–67.
   PubMed Web of Science ®Google Scholar
• Garnero P, Hausherr E, Chapuy MC et al. (1996). Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–8.
   PubMed Web of Science ®Google Scholar
• Garnero P, Sornay-Rendu E, Claustrat B et al. (2000b). Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study J Bone Miner Res 15:1526–36.
   PubMed Web of Science ®Google Scholar
• Gelb BD, Shi GP, Chapman HA et al. (1996). Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236–8.
   PubMed Web of Science ®Google Scholar
• Gertz BJ, Clemens JD, Holland SD et al. (1998). Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102–6.
   PubMed Web of Science ®Google Scholar
• Goldfine AB. (2008). The rough road for rosiglitazone. Curr Opin Endocrinol Diabetes Obes 15:113–17.
   PubMedGoogle Scholar
• Goodsaid F, Frueh F. (2007). Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 9:E105–8.
   PubMed Web of Science ®Google Scholar
• Grey A. (2008). Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19:129–37.
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G et al. (2007). The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305–10.
   PubMed Web of Science ®Google Scholar
• Hansdottir H, Franzson L, Prestwood K et al. (2004). The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 52:779–83.
   PubMed Web of Science ®Google Scholar
• Henriksen K, Byrjalsen I, Nielsen RH et al. (2009). A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol 616:340–5.
   PubMed Web of Science ®Google Scholar
• Hinoi E, Gao N, Jung DY et al. (2008). The sympathetic tone mediates leptin’s inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 183:1235–42.
   PubMed Web of Science ®Google Scholar
• Hoegh-Andersen P, Tanko LB, Andersen TL et al. (2004). Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther 6:R169–80.
   PubMed Web of Science ®Google Scholar
• Hwang JS, Tu ST, Yang TS et al. (2006). Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 17:373–8.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–43.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM et al. (2008). Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845–51.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Henriksen K, Leeming DJ et al. (2009). Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14:181–202.
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Martin TJ, Bollerslev J et al. (2007). Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487–94.
   PubMed Web of Science ®Google Scholar
• Karsenty G. (2006). Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 4:341–8.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Zhao H, Kitaura H et al. (2006). Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152–60.
   PubMed Web of Science ®Google Scholar
• Kim SW, Park DJ, Park KS et al. (2005). Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52:667–74.
   PubMed Web of Science ®Google Scholar
• Kung AW, Pasion EG, Sofiyan M et al. (2006). A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 22:929–37.
   PubMed Web of Science ®Google Scholar
• Lee NK, Sowa H, Hinoi E et al. (2007). Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–69.
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Alexandersen P, Karsdal MA et al. (2006). An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 62:781–92.
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Byrjalsen I, Qvist P et al. (2008). Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation? BMC Cancer 8:180.
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Moore LB, Smith-Oliver TA et al. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953–6.
   PubMed Web of Science ®Google Scholar
• Lesko LJ, Atkinson AJ Jr. (2001). Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347–66.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhou J, Tang W et al. (2006). Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38–49.
   PubMed Web of Science ®Google Scholar
• Martin A, Vittoris R, David V et al. (2005). Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 146:3652–9.
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB et al. (2006). Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–31.
   PubMed Web of Science ®Google Scholar
• Meier C, Seibel MJ, Kraenzlin ME. (2009). Use of bone turnover markers in the real world: are we there yet? J Bone Miner Res 24:386–8.
   PubMed Web of Science ®Google Scholar
• Minisola S, Del FR, Piemonte S et al. (2008). Biochemical markers in glucocorticoid-induced osteoporosis. J Endocrinol Invest 31:28–32.
   PubMedGoogle Scholar
• Morioka T, Asilmaz E, Hu J et al. (2007). Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest 117:2860–8.
   PubMedGoogle Scholar
• Moyer-Mileur LJ, Slater H, Jordan KC et al. (2008). IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res 23:1884–91.
   PubMed Web of Science ®Google Scholar
• Nishi Y, Atley L, Eyre DE et al. (1999). Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 14:1902–8.
   PubMed Web of Science ®Google Scholar
• O’Neill RT. (2006). FDA’s critical path initiative: a perspective on contributions of biostatistics. Biom J 48:559–64.
   PubMed Web of Science ®Google Scholar
• Okabe R, Inaba M, Nakatsuka K et al. (2004). Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 22:127–31.
   PubMed Web of Science ®Google Scholar
• Okazaki R, Miura M, Toriumi M et al. (1999). Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46:795–801.
   PubMed Web of Science ®Google Scholar
• OMERACT. (1993). Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. 1993. Proceedings. Maastricht, The Netherlands, April 29-May 3, 1992. J Rheumatol 20:527–91.
   PubMedGoogle Scholar
• Overgaard K, Riis BJ, Christiansen C et al. 1989. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 299:477–9.
   PubMed Web of Science ®Google Scholar
• Quarles LD. (2008). Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118:3820–8.
   PubMed Web of Science ®Google Scholar
• Ravn P, Hosking D, Thompson D et al. (1999). Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–8.
   PubMed Web of Science ®Google Scholar
• Ravn P, Thompson DE, Ross PD et al. (2003). Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33:150–8.
   PubMed Web of Science ®Google Scholar
• Ravn P, Weiss SR, Rodriguez-Portales JA et al. (2000). Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 85:1492–7.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Henrotin Y, Christiansen C et al. (2001). Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif. Tissue Int. 69:130–17.
   PubMed Web of Science ®Google Scholar
• Robins SP, Woitge H, Hesley R et al. (1994). Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643–9.
   PubMed Web of Science ®Google Scholar
• Roodman GD. (1999). Cell biology of the osteoclast. Exp Hematol 27:1229–41.
   PubMed Web of Science ®Google Scholar
• Rosen CJ. (2007). The rosiglitazone story–lessons from an FDA Advisory Committee meeting. N Engl J Med 357:844–6.
   PubMed Web of Science ®Google Scholar
• Rosen J, Miner JN. (2005). The search for safer glucocorticoid receptor ligands. Endocr Rev 26:452–64.
   PubMed Web of Science ®Google Scholar
• Rosenquist C, Fledelius C, Christgau S et al. (1998). Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clin Chem 44:2281–9.
   PubMed Web of Science ®Google Scholar
• Rosenquist C, Qvist P, Bjarnason N et al. (1995). Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439–45.
   PubMed Web of Science ®Google Scholar
• Rousseau JC, Delmas PD. (2007). Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 3:346–56.
   PubMedGoogle Scholar
• Roux C, Garnero P, Thomas T et al. (2005). Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine 72:26–31.
   PubMed Web of Science ®Google Scholar
• Rzonca SO, Suva LJ, Gaddy D et al. (2004). Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401–6.
   PubMed Web of Science ®Google Scholar
• Sassi ML, Eriksen H, Risteli L et al. (2000). Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26:367–73.
   PubMed Web of Science ®Google Scholar
• Schaller S, Henriksen K, Hoegh-Andersen P et al. (2005). In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 3:553–80.
   PubMed Web of Science ®Google Scholar
• Schaller S, Henriksen K, Sveigaard C et al. (2004). The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144–53.
   PubMed Web of Science ®Google Scholar
• Schwartz AV. (2008). TZDs and bone: a review of the recent clinical evidence. PPAR Res 2008:297893.
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. (2006). Bone quality – the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–61.
   PubMed Web of Science ®Google Scholar
• Seibel MJ. (2005). Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26:97–122.
   PubMedGoogle Scholar
• Seibel MJ. (2006). Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 27:123–38.
   PubMedGoogle Scholar
• Shi Y, Yadav VK, Suda N et al. (2008). Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci U S A 105:20529–33.
   PubMed Web of Science ®Google Scholar
• Soroceanu MA, Miao D, Bai XY et al. (2004). Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203–16.
   PubMed Web of Science ®Google Scholar
• Sottile V, Seuwen K, Kneissel M. (2004). Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329–37.
   PubMed Web of Science ®Google Scholar
• Spiegelman BM, Flier JS. (1996). Adipogenesis and obesity: rounding out the big picture. Cell 87:377–89.
   PubMed Web of Science ®Google Scholar
• Tanko LB, Bagger YZ, Alexandersen P et al. (2004). Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19:1531–8.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Spiegelman BM. (2008). Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77:289–312.
   PubMed Web of Science ®Google Scholar
• van Brussel MS, Bultink IE, Lems WF. (2009). Prevention of glucocorticoid-induced osteoporosis. Expert Opin Pharmacother 10:997–1005.
   PubMed Web of Science ®Google Scholar
• Vihinen MK, Kolho KL, Ashorn M et al. (2008). Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol 159:693–8.
   PubMed Web of Science ®Google Scholar
• Woodcock J, Woosley R. (2008). The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59:1–12.
   PubMed Web of Science ®Google Scholar